About Aclaris Therapeutics, Inc.
https://www.aclaristx.comAclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.
CEO
Neal S. Walker D.O.,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 60
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BML CAPITAL MANAGEMENT, LLC
Shares:14.25M
Value:$39.05M
VIVO CAPITAL, LLC
Shares:8.89M
Value:$24.36M
VANGUARD GROUP INC
Shares:6.52M
Value:$17.85M
Summary
Showing Top 3 of 132
About Aclaris Therapeutics, Inc.
https://www.aclaristx.comAclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.3M ▲ | $19.91M ▲ | $-14.61M ▲ | -442.98% ▲ | $-0.12 ▲ | $-14.4M ▲ |
| Q2-2025 | $1.78M ▲ | $18.34M ▼ | $-15.43M ▼ | -868.26% ▲ | $-0.13 ▼ | $-16.79M ▲ |
| Q1-2025 | $1.46M ▼ | $19.03M ▼ | $-15.09M ▲ | -1.04K% ▲ | $-0.12 ▲ | $-17.66M ▼ |
| Q4-2024 | $9.21M ▲ | $99.58M ▲ | $-96.55M ▼ | -1.05K% ▼ | $-1.01 ▼ | $-13.93M ▼ |
| Q3-2024 | $4.35M | $12.41M | $-7.59M | -174.55% | $-0.11 | $-9.49M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $95.91M ▼ | $175.53M ▼ | $55.43M ▼ | $120.1M ▼ |
| Q2-2025 | $99.81M ▼ | $189.15M ▼ | $57.41M ▲ | $131.74M ▼ |
| Q1-2025 | $105.31M ▼ | $198.09M ▼ | $54.03M ▼ | $144.07M ▼ |
| Q4-2024 | $113.59M ▼ | $220.33M ▲ | $64.77M ▲ | $155.55M ▲ |
| Q3-2024 | $127.72M | $182.39M | $52.24M | $130.15M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-14.61M ▲ | $-10.93M ▼ | $13.83M ▲ | $-3.04M ▼ | $-146K ▲ | $-10.96M ▼ |
| Q2-2025 | $-15.43M ▼ | $-9.99M ▲ | $5.05M ▼ | $-9K ▲ | $-4.96M ▼ | $-10.01M ▲ |
| Q1-2025 | $-15.09M ▲ | $-13.06M ▼ | $19.12M ▲ | $-275K ▼ | $5.79M ▲ | $-13.1M ▲ |
| Q4-2024 | $-96.55M ▼ | $-8.94M ▼ | $-88.72M ▼ | $74.58M ▲ | $-23.08M ▼ | $-44.75M ▼ |
| Q3-2024 | $-7.59M | $22M | $2.79M | $22K | $24.82M | $22M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Contract research | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 License and Service | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Neal S. Walker D.O.,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 60
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BML CAPITAL MANAGEMENT, LLC
Shares:14.25M
Value:$39.05M
VIVO CAPITAL, LLC
Shares:8.89M
Value:$24.36M
VANGUARD GROUP INC
Shares:6.52M
Value:$17.85M
Summary
Showing Top 3 of 132